Proteomics is the large-scale study of sets of proteins. It provides an important platform to support research into the underlying causes of diseases. Proteomics can also identify important biomarkers that could inform early diagnosis of disorders and predict their life course and response to treatments.
The identification of new biomarkers is vital to the development of personalised medicine and the ability to group patients based on risk of disease or response to therapy. Once developed, personalised medicines can be used to treat of a range of biological disorders, including dementia, addiction, and psychosis.
The RMID Core Proteomics Facility provides protein and peptide analyses to King’s College London and NIHR Maudsley BRC researchers using mass spectrometry methods. Using the latest high resolution orbitrap mass spectrometer technology, the Facility offers peptide and protein identification, post-translational modification analysis as well as quantitation analysis of multiplexed samples using chemical tagging reagents such as SILAC and Tandem Mass Tags (TMT).
The Facility also offers expert advice in proteomics and mass spectrometry, including on high-quality sample preparation, data analysis and bioinformatics for service work, collaborations, and grant writing is offered.
The NIHR Maudsley BRC provides access to a range of technologies through the Proteomics Facility at King’s Health Partners.